Skip to content

Study · Randomized controlled trial · n = 66 · 1997

3 results

Nocturnal enuresis and daytime wetting: a multicentric trial with oxybutynin and desmopressin.

Caione P, Arena F, Biraghi M, Cigna RM, Chendi D, Chiozza ML, De Lisa A, De Grazia E, Fano M, Formica P, Garofalo S, Gramenzi R and 13 more

Show all authors

von Heland M, Lanza P, Lanza T, Maffei S, Manieri C, Merlini E, Miano L, Nappo S, Pagliarulo A, Paolini Paoletti F, Pau AC, Porru D, Artibani W

European urology1 Jan 1997Cited by 34 (Europe PMC)

PMID9187908 (opens in a new tab)DOI10.1159/000474507 (opens in a new tab)PepBankPUB-09187908
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In children with enuresis and voiding dysfunction, oxybutynin plus DDAVP showed 71% success versus 54% with oxybutynin alone.

    In plain wordsIn children with enuresis and voiding dysfunction, adding desmopressin to oxybutynin showed 71% success versus 54% with oxybutynin alone.

    Peptide
    Desmopressin
    Outcome
    IncreaseResponse with added DDAVP
    Study

    n = 48

    Comparator
    Oxybutynin alone
    Outcome group
    Urinary function · Kidney and urinary
    Studied dose
    Dose not stated · 6 weeksAs given in this study (human).

    Measurements

    Success rate
    71%
    oxybutynin plus DDAVP
    Success rate
    54%
    oxybutynin alone

    Source sentences

    Summary
    The patients treated with both oxybutynin and DDAVP showed a better response, with a 71% rate of success.
    2 context sentences
    Summary · context
    Of the patients with diurnal voiding disturbances and enuresis, those treated with oxybutynin alone had a 54% success rate.
    Summary · context
    48 patients with enuresis and voiding dysfunction were randomly assigned to a protocol with oxybutynin alone or oxybutynin plus DDAVP.
  2. 02HumanNon-randomized trialEfficacy outcome

    In children with monosymptomatic enuresis, DDAVP significantly reduced wet nights versus baseline.

    In plain wordsIn children with monosymptomatic enuresis, desmopressin reduced wet nights compared with baseline.

    Peptide
    Desmopressin
    Outcome
    DecreaseWet nights
    Study

    n = 66

    Comparator
    Baseline
    Outcome group
    Urinary function · Kidney and urinary
    Studied dose
    30 micrograms/day · intranasal · 6 weeksAs given in this study (human).

    Source sentences

    Summary
    Patients with monosymptomatic enuresis treated with DDAVP reported a significantly lower number of wet night during treatment than during the baseline period, with 79% showing a 'good' (6-7 dry nights/week) or 'intermediate' response (4-5 dry nights/week).
    1 context sentence
    Summary · context
    After a 2-week observation period, 66 patients with primary monosymptomatic enuresis were treated with DDAVP, 30 micrograms/day intranasally, for 6 weeks,
  3. 03HumanNon-randomized trialEfficacy outcome

    In children with monosymptomatic enuresis, 79% had a good or intermediate response to DDAVP.

    In plain wordsIn children with monosymptomatic enuresis, 79% had a good or intermediate response to desmopressin.

    Peptide
    Desmopressin
    Outcome
    Not applicableGood or intermediate response
    Study

    n = 66

    Outcome group
    Urinary function · Kidney and urinary
    Studied dose
    30 micrograms/day · intranasal · 6 weeksAs given in this study (human).

    Measurements

    Patients with good or intermediate response
    79%
    monosymptomatic enuresis, DDAVP 30 micrograms/day intranasal

    Source sentences

    Summary
    Patients with monosymptomatic enuresis treated with DDAVP reported a significantly lower number of wet night during treatment than during the baseline period, with 79% showing a 'good' (6-7 dry nights/week) or 'intermediate' response (4-5 dry nights/week).
    1 context sentence
    Summary · context
    After a 2-week observation period, 66 patients with primary monosymptomatic enuresis were treated with DDAVP, 30 micrograms/day intranasally, for 6 weeks,

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.